Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers.

Wilson PC, Lee MH, Appleton KM, El-Shewy HM, Morinelli TA, Peterson YK, Luttrell LM, Jaffa AA.

J Biol Chem. 2013 Jun 28;288(26):18872-84. doi: 10.1074/jbc.M113.472381. Epub 2013 May 9.

2.

The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G protein-independent signaling network.

Kendall RT, Strungs EG, Rachidi SM, Lee MH, El-Shewy HM, Luttrell DK, Janech MG, Luttrell LM.

J Biol Chem. 2011 Jun 3;286(22):19880-91. doi: 10.1074/jbc.M111.233080. Epub 2011 Apr 18.

3.

Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis.

Kendall RT, Lee MH, Pleasant DL, Robinson K, Kuppuswamy D, McDermott PJ, Luttrell LM.

J Biol Chem. 2014 Sep 19;289(38):26155-66. doi: 10.1074/jbc.M114.595728. Epub 2014 Jul 31.

4.

Vasopressor meets vasodepressor: The AT1-B2 receptor heterodimer.

Quitterer U, AbdAlla S.

Biochem Pharmacol. 2014 Apr 1;88(3):284-90. doi: 10.1016/j.bcp.2014.01.019. Epub 2014 Jan 22.

5.

Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.

Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P.

J Biol Chem. 2015 Jun 19;290(25):15835-54. doi: 10.1074/jbc.M114.627356. Epub 2015 May 1.

6.

The Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling.

Shen B, Harrison-Bernard LM, Fuller AJ, Vanderpool V, Saifudeen Z, El-Dahr SS.

J Am Soc Nephrol. 2007 Apr;18(4):1140-9. Epub 2007 Mar 7.

7.

Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension.

AbdAlla S, Abdel-Baset A, Lother H, el Massiery A, Quitterer U.

J Mol Neurosci. 2005;26(2-3):185-92.

PMID:
16012192
8.

AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration.

AbdAlla S, Lother H, Quitterer U.

Nature. 2000 Sep 7;407(6800):94-8.

PMID:
10993080
9.
10.

Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW.

J Pharmacol Exp Ther. 2010 Dec;335(3):572-9. doi: 10.1124/jpet.110.173005. Epub 2010 Aug 26.

11.

Farnesoid X receptor regulates vasoreactivity via Angiotensin II type 2 receptor and the kallikrein-kinin system in vascular endothelial cells.

Zhang R, Ran H, Peng L, Zhang Y, Shen W, Sun T, Cao F, Chen Y.

Clin Exp Pharmacol Physiol. 2016 Mar;43(3):327-34. doi: 10.1111/1440-1681.12535.

PMID:
26710942
12.

Investigation of the fate of type I angiotensin receptor after biased activation.

Szakadáti G, Tóth AD, Oláh I, Erdélyi LS, Balla T, Várnai P, Hunyady L, Balla A.

Mol Pharmacol. 2015 Jun;87(6):972-81. doi: 10.1124/mol.114.097030. Epub 2015 Mar 24.

13.

Activation of ERK, JNK, Akt, and G-protein coupled signaling by hybrid angiotensin II AT1/bradykinin B2 receptors expressed in HEK-293 cells.

Yu J, Lubinsky D, Tsomaia N, Huang Z, Taylor L, Mierke D, Navarro J, Miraz O, Polgar P.

J Cell Biochem. 2007 May 1;101(1):192-204.

PMID:
17212359
14.

An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies.

Ceravolo GS, Montezano AC, Jordão MT, Akamine EH, Costa TJ, Takano AP, Fernandes DC, Barreto-Chaves ML, Laurindo FR, Tostes RC, Fortes ZB, Chopard RP, Touyz RM, Carvalho MH.

PLoS One. 2014 Nov 4;9(11):e111117. doi: 10.1371/journal.pone.0111117. eCollection 2014.

15.

Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen.

Yu J, Taylor L, Rich C, Toselli P, Stone P, Green D, Warburton R, Hill N, Goldstein R, Polgar P.

J Cell Physiol. 2012 May;227(5):2013-21. doi: 10.1002/jcp.22929.

16.

Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.

Bonde MM, Hansen JT, Sanni SJ, Haunsø S, Gammeltoft S, Lyngsø C, Hansen JL.

PLoS One. 2010 Nov 30;5(11):e14135. doi: 10.1371/journal.pone.0014135.

17.

The angiotensin II type 1 receptor antagonist Losartan binds and activates bradykinin B2 receptor signaling.

Bonde MM, Olsen KB, Erikstrup N, Speerschneider T, Lyngsø C, Haunsø S, Nielsen MS, Sheikh SP, Hansen JL.

Regul Pept. 2011 Feb 25;167(1):21-5. doi: 10.1016/j.regpep.2010.11.003. Epub 2010 Nov 27.

PMID:
21115072
18.

Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors.

Turu G, Szidonya L, Gáborik Z, Buday L, Spät A, Clark AJ, Hunyady L.

FEBS Lett. 2006 Jan 9;580(1):41-5. Epub 2005 Dec 6.

19.

Allosteric modulation of β-arrestin-biased angiotensin II type 1 receptor signaling by membrane stretch.

Tang W, Strachan RT, Lefkowitz RJ, Rockman HA.

J Biol Chem. 2014 Oct 10;289(41):28271-83. doi: 10.1074/jbc.M114.585067. Epub 2014 Aug 28.

20.

Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs.

Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, Laporte SA.

Sci Signal. 2012 Apr 24;5(221):ra33. doi: 10.1126/scisignal.2002522.

Supplemental Content

Support Center